This application relates to solabegron zwitterion useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to pharmaceutical compositions and methods of treatment utilizing the solabegron zwitterion for treating lower urinary tract symptoms. This application also relates to methods of preparing solabegron hydrochloride from the solabegron zwitterion.

The present invention relates to a kit, comprising at least one cold spray and at least one dosage form for transdermally administering at least one pharmaceutically active ingredient, to said kit for use in the treatment of a patient, to the use of a cold spray in order to shorten the resorption delay time in the application of a dosage form for transdermally administering at least one pharmaceutically active ingredient, and to a method for treating a patient.

The present invention relates to a kit, comprising at least one cold spray and at least one dosage form for transdermally administering at least one pharmaceutically active ingredient, to said kit for use in the treatment of a patient, to the use of a cold spray in order to shorten the resorption delay time in the application of a dosage form for transdermally administering at least one pharmaceutically active ingredient, and to a method for treating a patient.

The present invention relates to a kit, comprising at least one cold spray and at least one dosage form for transdermally administering at least one pharmaceutically active ingredient, to said kit for use in the treatment of a patient, to the use of a cold spray in order to shorten the resorption delay time in the application of a dosage form for transdermally administering at least one pharmaceutically active ingredient, and to a method for treating a patient.

Disclosed herein are agents that enhance muscle stem cell engraftment, as well as methods and compositions using the same.

Disclosed herein are agents that enhance muscle stem cell engraftment, as well as methods and compositions using the same.

Provided is a dental pretreatment material for dental tissue regeneration by use of dental pulp stem cells, particularly a dental pretreatment material effectively enabling dental tissue regeneration even by use of dental pulp stem cells of middle-aged or older individuals. The dental pretreatment material is characterized by comprising a serine protease, specifically trypsin. The dental pretreatment material comprising trypsin is used as an injection into a root canal before a root canal filling material comprising dental pulp stem cells and an extracellular matrix is inserted into the root canal as an attempt to regenerate a dental pulp and a dentin. The root canal filling material includes an ALK5 inhibitor, a CCR3 antagonist, or a CCL11 neutralizing antibody.

Provided is a dental pretreatment material for dental tissue regeneration by use of dental pulp stem cells, particularly a dental pretreatment material effectively enabling dental tissue regeneration even by use of dental pulp stem cells of middle-aged or older individuals. The dental pretreatment material is characterized by comprising a serine protease, specifically trypsin. The dental pretreatment material comprising trypsin is used as an injection into a root canal before a root canal filling material comprising dental pulp stem cells and an extracellular matrix is inserted into the root canal as an attempt to regenerate a dental pulp and a dentin. The root canal filling material includes an ALK5 inhibitor, a CCR3 antagonist, or a CCL11 neutralizing antibody.

Compositions may include a therapeutic that is released from the composition to treat any number of ailments or conditions (e.g., pain, infection, cancer, osteoporosis) or to help accelerate local tissue regeneration (e.g., growth hormone, bone morphogenic protein) or to assist with surgical or therapeutic treatment (e.g., imaging modality), or any of a combination thereof.

The present application relates to method of vaccinating a subject against infection by an enveloped virus. The method includes providing a compound of the Formula (I) as described herein, and contacting the compound of Formula (I) with an isolated enveloped virus, having a membrane, to inactivate the membrane of the isolated enveloped virus. The subject is then treated with the enveloped virus having an inactivated membrane to vaccinate the subject against the enveloped virus. Further disclosed is an ex vivo vaccine composition including the compound of Formula (I) and an enveloped virus.